Highlights
-
Minimising treatment-related cardiovascular disease (CVD) in cancer survivors is crucial to maximising healthy survivorship.
-
Predictive models that aid in identifying persons at highest risk for such toxicities as well as primary prevention may be approached to decrease CVD after cancer treatments.
-
We performed a scoping literature review on prediction and primary prevention of CVD in cancer survivors and graded the studies with a Level of Evidence.
-
We identified studies with moderate to good strength and up to now limited evidence to recommend primary preventive strategies in unselected patients treated with potentially cardiotoxic oncologic therapies. Some predictive models exist, but those lack methodological robustness to be implemented in clinical use.
Background
Methods
Level | 1 | a | Systematic review of randomised controlled trials |
b | Single randomised controlled trial | ||
Level | 2 | a | Systematic review of cohort studies |
b | Individual cohort study | ||
c | “Outcomes” research | ||
Level | 3 | a | Systematic review of Case-Control studies |
b | Individual Case-Control study | ||
Level | 4 | Case-series | |
Level | 5 | Expert opinion |
Study | Population | Components of model | Discriminative value | Strength | Consecutive step |
---|---|---|---|---|---|
Ezaz et al. [15] | From SEER database: N = 1664 pts. treated for HER2+ BC with systemic therapies | 1 point: past medical history of hypertension, diabetes, or age 75–79 years. 2 points: history of coronary artery disease, renal failure, or atrial fibrillation or flutter, having received any chemotherapy or > 80 years of age | Three risk groups: low (0 to 3 points), medium (4 to 5 points), and high (≥6 points) risk strata with 3-year CE rates of 16.2, 26.0, and 39.5%, respectively | Training set of 70%, internal validation in the other 30% with strong performance of the model | Validation in additional external cohorts. No information on cardiovascular medication use |
Rushton et al. [16] | N = 143 patients with HER2+ BC referred to a cardio-oncology clinic at a tertiary care center | Sensitivity analysis to validate model composed by Ezaz et a [16] | Low risk: 42% CE rate, 13% permanent HF Moderate risk: 64% CE rate, 14% permanent HF High risk: 30% CE rate, 20% permanent HF | Low cardiac risk score had a negative predictive value of 94% for permanent cardiotoxicity. | Highly selected population. Sub-optimal performance in high risk group. |
Fogarassy et al. [8] | Nationwide health care databases, N = 8068 BC pts. treated with epirubicin | Risk-prediction score for HF composed of age, diabetes mellitus, hypertension, coronary artery disease, stroke, epirubicin dose, docetaxel dose, capecitabine, gemcitabine, bevacizumab and cancer stage | Five score point categories and corresponding risk for HF; score 1–7 HF 2.1%, score 8–9 HF 5.0%, score 10–12 HF 10.3%, score 13–18 HF 22.1%, score 19–26 HF 31.7% | Large dataset, Training set of 70%, internal validation in the other 30% | Information on cardiovascular medication use. External validation. |
Romond et al. [17] | Analysis from NSABP B-31 trial, N = 1830 pts. with HER2+ BC | Retrospective regression analysis to reveal predictors for cardiac events: formula to calculate cardiac risk score | Cardiac risk score based on age and baseline LVEF by MUGA | High discriminate ability (C-index 72%) in associating the length of time to a cardiac event with the probability of not experiencing CEs. | No external validation of the risk score |
Hermann et al. [18] | Literature- and expert-based recommendation | Type of treatment, age, gender, history of CVD or presence of risk factors for CVD | No statistical validation | Easily accessible variables | Test algorithm in patient population for clinically relevant endpoints. |
Abdel-Qadir et al. [19] | Real-world population EBC Ontario 2003–2015, N = 90,104 (2/3 training, 1/3 validation set) | Risk-prediction score for MACE composed of age, hypertension, diabetes, ischaemic heart disease, atrial fibrillation, HF, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, and chronic kidney disease | Ten-year MACE incidence was > 40-fold higher for patients in the highest score decile compared to the lowest. The c-index was 81.9% (95% confidence interval 80.9–82.9%) at 5 years and 79.8% (78.8–80.8%) at 10 years in the validation cohort, with good agreement between predicted and observed MACE incidence. | Clinically relevant long-term outcome | No incorporation of cancer and treatment-related variables |
Dranitsaris et al. [20] | Metastatic breast cancer pts. treated with anthracyclines (doxorubicin or liposomal doxorubicin), N = 509 | Risk scoring algorithm (range 0–62) based on number of cumulative cycles, patient age and weight, previous anthracycline exposure and poor performance statu | A ROC analysis had an area under the curve (AUC) of 0.84 (95% CI: 0.79–0.89). A precycle risk score cutoff of ≥30 to < 40 was identified to optimally balance sensitivity (58.5%) and specificity (89.0%). | Easily accesible variables | Validation in external cohorts. Add information on risk factors for CVD and medication use . |
Review / main text
Prediction of future CVD in cancer patients
Prevention of future CVD during oncological treatments
Intervention (LOE) | Population | Study design | Primary outcome | Result |
---|---|---|---|---|
ACEI/ARB/beta-blockers | Meta-analysis N = 2301 early breast cancer pts., HER2+/− [28] | RCT’s ACEI, ARB and/or BB | Change in LVEF | Standardized mean difference LVEF baseline vs treatment completion for all groups: − 2.36 [95% CI: − 3.23 to − 1.49] |
Meta-analysis N = 633 pts. [29] | RCT’s carvedilol vs placebo | Occurrence of low LVEF | Low LVEF carvedilol vs. placebo 3.2% vs. 5.8% (OR: 0.42; 95% confidence interval: 0.18–0.99; p = 0.05). LVEF reduction carvedilol vs. placebo: mean difference 2.41% (95% CI: 0.01–4.81; p = 0.05). | |
Meta-analysis N = 1984 pts. [30] | RCT’s with neurohormonal therapy vs placebo (BB, ACEi, ARB, mineralocorticoid receptor antagonists) | Change in LVEF | Intervention arms had a higher LVEF on follow-up (standardized mean difference + 1.04% (95% CI 0.57–1.50) but significant heterogeneity (I2 96%) | |
N = 69 pts. with malignancy treated with anthracycline [29] | Prospective RCT, single-blind, enalapril vs. placebo | Change in LVEF from baseline to 6 months | Preserved LVEF in enalapril group (p = 0.58), decreased LVEF in control group (p < 0.001) | |
N = 40 pts. with non-Hodgkin lymphoma, combination (CHOP) chemotherapy [31] | Prospective RCT, open-label, valsartan (80 mg/day) vs. control | Explorative; changes in neurohumoral, echocardiographic, electrocardiographic markers during therapy | Compared to control, valsartan significantly inhibited the dilatation of LVDd (P = 0.01), elevation of BNP (P = 0.001), and prolongation of the QTc interval and QTc dispersion (P = 0.0009 and P = 0.02, respectively) after CHOP chemotherapy | |
N = 49 pts., different malignancies treated with epirubicin [32] | Prospective RCT, telmisartan vs. placebo | Change in strain rate by echocardiography compared to baseline. Biomarkers. | Decrease in strain rate in both arms, but recovery to baseline values in telmisartan group. Lower levels of inflammatory marker IL-6 in telmisartan group compared to control. No differences in (changes in) LVEF. | |
N = 36 acute leukemia receiving intensive chemotherapy, N = 54 hematologic malignancies receiving stem cell transplantation. LVEF ≥50% at baseline [33]. | Prospective RCT, carvedilol + enalapril vs. control group | Change in LVEF by echocardiography | Preserved LVEF in intervention arm (− 3.28 [− 5.49 to − 1.07] in control group, − 0.17 [− 2.24 to 1.90] intervention group, difference − 3.11%, p = 0.04) In control group lower incidence death/heart failure (6.7% vs. 22%, p = 0.036) and of death, heart failure, or a final LVEF < 45% (6.7% vs. 24.4%, p = 0.02). | |
N = 147 lymphoma pts., doxorubicin combination chemotherapy [34] | Prospective randomised three-arm trial (metoprolol, enalapril or placebo) | Clinical heart failure and subclinical cardiotoxicity | No statistically significant differences in the study arms (up to 10 yr follow-up) [35] | |
N = 468 early HER2+ breast cancer pts., treated with trastuzumab +/− anthracyclines [36] | Prospective randomised three-arm trial (lisinopril, carvedilol or placebo) | Cardiotoxic event | Cardiotoxicity occurred in 32% patients on placebo, 29% on carvedilol, and 30% on lisinopril. | |
N = 121 pts. with early breast cancer treated with adjuvant chemotherapy including anthracyclines [37] | Prospective 2 × 2 factorial placebo-controlled double-blind RCT. | Change in LVEF | The overall decline in LVEF was 2.6% (95% CI 1.5, 3.8) in the placebo group and 0.8 (95% CI − 0.4, 1.9) in the candesartan group in the intention-to-treat analysis (P-value for between-group difference: 0.026). No effect of metoprolol on the overall decline in LVEF was observed. | |
N = 94 pts. with early HER2+ breast cancer [38] | Prospective randomised three-arm trial (perindopril, bisoprolol or placebo) | Trastuzumab-mediated left ventricular remodeling on ultrasound | No difference between groups | |
Statins | N = 40 pts. with malignancy planned for anthracycline treatment [39] | Prospective RCT 6 months of atorvastatin (40 mg/day) vs. control | Rate LVEF < 50% | No difference primary endpoint (p = 0.18), but mean change in LVEF in control group significantly larger than in statin group (− 7.9 ± 8.0 vs. 1.3 ± 3.8, p < 0.001) |
Other | Meta-analysis of 2177 breast cancer pts. treated with anthracyclines +/− trastuzumab [40] | Dexrazoxane vs placebo | Rate of CHF and cardiac events | Reduction in CHF (RR: 0.19; 95% CI: 0.09 to 0.40, P < 0.001) and cardiac events (RR: 0.36; 95% CI: 0.27 to 0.49, p < 0.001) |
N = 27 pts. treated with doxorubicin [41] | Prospective open label RCT, sildanefil (100 mg 3 times daily) vs. control | Change in mean LVEF | No difference. No difference in (changes in) serum troponin I. |
Preventive medication: (ACEI/ARB/beta-blockers)
Preventive medication: statins
Preventive medication: aspirin/anticoagulants
Preventive medication: dexrazoxane and sildenafil
Lifestyle interventions before and during treatment initiation
Smoking cessation
Diet changes and weight loss
Physical exercise
Strategies for prevention of CVD after cancer treatment completion
Ongoing intervention trials aiming to decrease CVD in relation to cancer treatments
ClinicalTrials.gov ID | Population | Intervention | Primary endpoint | Estimated enrollment |
---|---|---|---|---|
NCT03964142 | BC pts. treatment with anthracyclines and / or anti-HER-2 antibodies | comprehensive cardiac rehabilitation program including supervised exercise training | Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography | 340 |
NCT04476576 | hemato-oncological diseases that initiate chemotherapy | Aerobic exercise Vs Flexibility exercise | Change in systolic longitudinal strain (exercise of flexibility and balance). [Time Frame: 6 months] | 38 |
NCT03850171 | Pts with breast cancer or lymphoma scheduled for anthracycline-based chemotherapy | Exercise Training | Changes from baseline in left ventricular (LV) global longitudinal strain (GLS) [Time Frame: week 13] | 120 |
NCT03787966 | BC pts. scheduled for surgery and adjuvant chemotherapy | Exercise training before or before and after medical treatment | Left ventricular ejection fraction [Time Frame: Participants will be followed over 12 months] | 100 |
NCT03711110 | Elderly pts. Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myelom | Intensive cardiovascular monitoring | All-cause mortality [Time Frame: Two (mid-term analysis) and 5 years of follow-up] | 514 |
NCT03186404 | Pts with BC, lymphoma, leukemia or sarcoma scheduled for anthracycline-based chemotherapy | Atorvastatin | Cardiac MRI measured LVEF within 4 weeks of anthracycline completion | 112 |
NCT04023110 | breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab | Carvedilol | Left Ventricular Ejection Fraction (LVEF) [Time Frame: up to 24 months | 110 |
NCT03265574 | Pts with BC and lymphoma treated with anthracyclines | Enalapril | Cardiac troponin T release [Time Frame: One month after last dose of anthracycline | 170 |
NCT03650205 | cancer pts. treated with anthracyclines | Ivabradine | Ventricular function [Time Frame: 365 days after randomization] Reduction in global longitudinal strain of at least 10% (GLS) | 160 |
NCT04030546 | cancer pts. treated with anthracyclines | Ivabradine | Change in left venticular dysfunction by global longitudinal strain (GLS). [Time Frame: 1, 3 and 6 months] Change in global longitudinal strain (GLS) at least by 3%. | 128 |
NCT04429633 | breast cancer patients treated with adjuvant trastuzumab. | Candesartan | Left ventricular ejection fraction (LVEF) [Time Frame: at months 3,6,9,12,18] | 136 |
NCT02818517 | Two cohorts, one prospective group will include all oncologic patients who will be evaluated in the cardio-oncology clinic | ACE inhibitors or beta blockers | ECho-global strain [Time Frame: 2 years | 1000 |
NCT04092309 | Pts undergoing Hematopoietic Stem Cell Transplantation | Sacubitril-Valsartan | Left Ventricular Function, Global Longitudinal Strain, arterial stiffness, glycocalyx thickness [Time Frame: 2 years] | 90 |
NCT02943590 | Pts with newly diagnosed NHL and HL, anthracycline-based therapy | Atorvastatin | Left ventricular Ejection Fraction (LVEF) [Time Frame: 12 months] | 270 |
NCT04632407 | BC pts. during adjuvant chemotherapy | Dietary Supplement: Flax “milk”Dietary Supplement: Oat fibre “milk” | Left ventricular ejection fraction (LVEF) change [Time Frame: 1 year] | 60 |
NCT03934905 | BC pts. neoadjuvant treatment incl doxorubicin | sulforaphane | Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies [Time Frame: At baseline and 1 year from baseline assessment.] | 70 |
NCT04361240 | Breast cancer radiotherapy | Radiation: Proton vs Photon Radiation | Change in echocardiography derived LVEF from baseline | 155 |
Conclusion
Timing | Intervention | Effect | Level of Evidence | Reference |
---|---|---|---|---|
Pre-treatment | Use of predictive models for future CVD | Risk groups to predict rate of cardiac events during 3 year follow-up after curative (HER2+) BC treatment | 2b | [15] |
During treatment | ACEi/ARB | Mean difference in delta LVEF −2.36% in pts. with early HER2+/− BC | 1a | [28] |
Beta-blocker | 2,6% lower incidence of LVEF < 50% compared to placebo, NNT 38 | 1a | [29] | |
Statins | No difference in LVEF < 50% | 1b | [39] | |
Aspirin/anticoagulants | n.a. | n.a. | ||
Other drugs; dexrazoxane | Reduces risk of CHF and cardiac events | 1a | [40] | |
Other drugs; sildenafil | No difference LVEF-declines | 1b | [42] | |
Smoking cessation | Circumstantial: smokers increased reisk for cardiac toxicity related to radiotherapy | n.a. | ||
Weight loss | Circumstantial: reduction non-BC mortality in BC survivors | n.a. | ||
Physical exercise | Hypothesis generating for ongoing RCT’s | 5 | ||
Post treatment | Primary prevention | Indirect evidence from general population | n.a. |